-
TARA Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Protara Therapeutics (TARA)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 52.50 mm | 52.50 mm | 52.50 mm | 52.50 mm | 52.50 mm | 52.50 mm |
Cash burn (monthly) | 12.61 mm | (no burn) | 4.11 mm | 3.82 mm | 2.81 mm | 2.93 mm |
Cash used (since last report) | 50.71 mm | n/a | 16.53 mm | 15.38 mm | 11.31 mm | 11.80 mm |
Cash remaining | 1.79 mm | n/a | 35.97 mm | 37.12 mm | 41.19 mm | 40.70 mm |
Runway (months of cash) | 0.1 | n/a | 8.8 | 9.7 | 14.7 | 13.9 |
13F holders | Current |
---|---|
Total holders | 20 |
Opened positions | 4 |
Closed positions | 23 |
Increased positions | 8 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 5.60 bn |
Total shares | 3.71 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
StemPoint Capital | 942.86 k | $1.73 bn |
Vanguard | 759.61 k | $1.39 bn |
CVI Investments | 600.38 k | $2.18 mm |
Renaissance Technologies | 336.74 k | $616.23 mm |
Two Sigma Investments | 185.22 k | $338.96 mm |
Oppenheimer & Co | 179.13 k | $327.80 mm |
Geode Capital Management | 170.04 k | $311.20 mm |
Two Sigma Advisers | 151.62 k | $277.46 mm |
BlackRock | 116.98 k | $214.07 mm |
Bridgeway Capital Management | 49.20 k | $90.04 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Jan 25 | Jacqueline Zummo | Common Stock | Grant | Acquire A | No | No | 0 | 24,500 | 0.00 | 126,639 |
24 Jan 25 | Jacqueline Zummo | Stock Option Common Stock | Grant | Acquire A | No | No | 4.53 | 146,000 | 661.38 k | 146,000 |
24 Jan 25 | Hannah Fry | Common Stock | Grant | Acquire A | No | No | 0 | 9,500 | 0.00 | 38,942 |
24 Jan 25 | Hannah Fry | Stock Option Common Stock | Grant | Acquire A | No | No | 4.53 | 55,000 | 249.15 k | 55,000 |
24 Jan 25 | Patrick Fabbio | Common Stock | Grant | Acquire A | No | No | 0 | 23,500 | 0.00 | 45,500 |
24 Jan 25 | Patrick Fabbio | Stock Option Common Stock | Grant | Acquire A | No | No | 4.53 | 140,000 | 634.20 k | 140,000 |
24 Jan 25 | Shefferman Jesse | Common Stock | Grant | Acquire A | No | No | 0 | 65,000 | 0.00 | 994,022 |
24 Jan 25 | Shefferman Jesse | Stock Option Common Stock | Grant | Acquire A | No | No | 4.53 | 387,000 | 1.75 mm | 387,000 |
21 Jan 25 | Patrick Fabbio | Common Stock | Payment of exercise | Dispose F | No | No | 4.76 | 3,061 | 14.57 k | 18,939 |